We have built up an exciting portfolio of investments in high potential businesses across a range of therapeutic areas, technologies, geographies and clinical contexts.
20 February 2018
Evofem Biosciences, Inc., (NASDAQ: EVFM), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evaluating Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy. Trial data is expected in the first quarter of 2019.
08 February 2018
Epic Sciences, Inc. (Epic) announces that it will present data, in conjunction with Endocyte, Inc., comparing its proprietary single cell CTC analysis to PSMA targeted imaging in mCRPC patients to provide insight into disease heterogeneity and identify potential therapeutic resistance mechanisms.